Hasil Pencarian - Barbara Ink

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies

    Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two... oleh Joseph F Merola, Philip J Mease, Dafna D Gladman, M Elaine Husni, Nadine Goldammer, Jason Coarse, William Tillett, Vanessa Taieb, Jeremy Lambert, Barbara Ink

    Diterbitkan 2024-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis

    Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic... oleh Laure Gossec, Ana-Maria Orbai, Maarten de Wit, Dafna D Gladman, Laura C Coates, Alexis Ogdie, Vanessa Taieb, Jeremy Lambert, Barbara Ink, Christopher G Pelligra, Valérie Ciaravino

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

    Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies oleh Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... oleh Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: